Triptorelin 0.1 mg
Druga single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
Other names: Decapeptyl 0.1 mg
NCT Number: NCT03039049
Purpose:The aim of this project is to prospectively determine whether a single dose of GnRH-agonist administered at the time of implantation increases or not the reproductive outcome in patients undergoing in vitro fertilization ( IVF)/ intracytoplasmatic sperm injection(ICSI) triggered by a GnRH-agonist followed by a small bolus of human chorionic gonadotropin (hCG 1500 IU) the day of oocyte retrieval.
Looking for future studies?
Notify Me18 year–40 year
Female
Interventional
Phase 3
Ibnrochd Clinic, Constantine, Algeria
It has been reported in previous publications that the ovarian hyperstimulation syndrome (OHSS) was eliminated when GnRH agonist was used to trigger ovulation and the delivery rate has improved after modified luteal support especially when a small bolus of hCG is used on the day of oocyte retrieval. (OMEGA/HCG 1500 IU).
However, a risk difference of 7% in delivery rates is still in favor of HCG trigger. Thus, further modifications in the luteal phase supplementation are required in order to optimise the reproductive outcome after GnRH-agonist triggering.
Recently, many papers showed, that independently of the GnRH analogue used to prevent the premature LH surge, the addition of GnRH-agonist during the luteal phase seems to be beneficial in terms of pregnancy. Nevertheless, their use in practice is not yet admitted because of controversial results in terms of efficacy and safety particularly on the conceptus.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Female age < 40 years No uterine (fibroids, mullerian malformations), ovarian ( endometrioma) or adnexa (hydrosalpinx) abnormalities• Baseline FSH and LH < 12 IU/l.Patients with at least one embryo at transfer time
Exclusion criteria
a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
Other names: Decapeptyl 0.1 mg
Time frame: Time Frame: 5 weeks after IVF/ICSI
number of gestational sacs per number of embryos transferred
Time frame: Time Frame: 2 weeks after IVF/ICSI
confirmed by beta-hCG 14 days post embryo transfer
Time frame: Time Frame: 12 weeks after IVF/ICSI
presence of foetal heart beat at 12 weeks of gestation
Time frame: Time Frame: 26 weeks after IVF/ICSI
birth of baby beyond 26 weeks of gestation
Time frame: Time Frame: miscarriage before 5 weeks of gestation
loss of embryo before 5 weeks of gestation, chemical pregnancy and extra-uterine pregnancy
Time frame: Time Frame: from date of triggering until 2 weeks after pregnancy test]
early and late onset Ovarian hyper stimulation syndrome
Centre Hospitalier Universitaire Ibn Rochd
Other
GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Mid-luteal Bolus of GnRHa: a Randomised Controlled Trial.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06659692
Genital Diseases, Infertility
Toronto, Ontario, Canada
View Trial DetailsNCT06924437
Abnormal Uterine Bleeding (AUB), Endometrial Polyp
Sohag, Egypt
View Trial DetailsNCT01511588
Adolescents, Amenorrhea
Bethesda, Maryland, United States
View Trial DetailsNCT07399535
Adnexal Diseases, Cysts
Karachi, Sindh, Pakistan
View Trial Details